MDxHealth, Teva Pharmaceuticals Collaborate
News Sep 01, 2016
MDxHealth SA has announced that it has signed a distribution agreement with Teva Pharmaceuticals to offer its SelectMDx(TM) for Prostate Cancer test to Teva's urology customers throughout Israel. Under the terms of the three-year agreement, Teva Pharmaceuticals will be the exclusive distributor of the SelectMDx for Prostate Cancer test in Israel. Samples will be sent to MDxHealth's clinical diagnostic laboratory in Nijmegen, The Netherlands for analysis. Teva will reimburse MDxHealth for all the testing services.
Dr. Jan Groen, Chief Executive Officer of MDxHealth, stated: "We are pleased to expand our longstanding partnership with Teva and allow patients in Israel to access SelectMDx, a test which is ideally suited to address an unmet need in urology. SelectMDx provides a non-invasive, 'liquid biopsy' test which improves patient selection for prostate biopsy."
Sapir Avinoam, VP and General Manager of Teva Israel, added: "The SelectMDx test opens up the opportunity to address a broader segment of patients at risk for prostate cancer and being considered for an invasive biopsy procedure. The test further complements our portfolio of molecular tests and services, allowing us to better serve our physician base and improve patient outcomes."
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE